Related Experiment Videos
Predictive value of anti-DNA antibody and selected laboratory studies in systemic lupus erythematosus
Insights
Certain biomarkers like anti-DNA antibodies, hemoglobin, and creatinine levels can predict the course of systemic lupus erythematosus (SLE). These markers, especially anti-DNA, show significant correlation with disease progression and current clinical status in SLE patients.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease with variable clinical manifestations and prognosis.
- Predicting the long-term morbidity and mortality in SLE patients is crucial for effective disease management.
Purpose of the Study:
- To evaluate the predictive value of clinical and laboratory variables for the morbidity and mortality in patients with SLE.
- To identify key biomarkers that correlate with the subsequent course and concurrent clinical status of SLE.
Main Methods:
- Retrospective study involving 71 patients diagnosed with SLE.
- Analysis of various clinical and laboratory variables, including anti-DNA antibody, hemoglobin, creatinine, and C3 levels.
- Patients were followed for an average of 57 months to assess disease progression and outcomes.
Main Results:
- Initial anti-DNA antibody, hemoglobin, and creatinine levels showed significant correlation (p < 0.05) with the subsequent course of SLE.
- Anti-DNA antibody levels demonstrated a stronger correlation with disease course in patients diagnosed within 12 months of initial evaluation.
- At the most recent evaluation, anti-DNA, hemoglobin, creatinine, and C3 levels strongly correlated (p < 0.01-p < 0.001) with the concurrent clinical status.
Conclusions:
- Anti-DNA antibody, hemoglobin, and creatinine levels are significant predictors of the subsequent course of SLE, though not definitive for final outcome.
- These biomarkers, along with C3 levels, are strongly associated with the current clinical status of SLE patients.
- The findings highlight the utility of specific biomarkers in monitoring SLE progression and clinical status.
Abstract:
In a retrospective study of 71 patients with systemic lupus erythematosus (SLE), a large number of clinical and laboratory variables were studied in order to determine their predictive value of morbidity and mortality. Patients were followed for an average of 57 months. Anti-DNA antibody, hemoglobin and creatinine levels at initial evaluation correlated significantly (p less than 0.05) for subsequent course of SLE, although each parameter was not a good predictor for final outcome. Anti-DNA correlated better with subsequent course in patients who were diagnosed within 12 months of the initial evaluation. By comparison, other measured parameters were not predictive at all. Anti-DNA, hemoglobin, creatinine and C3 levels at the time of most recent evaluation (date last seen) correlated strongly (p less than 0.01-p less than 0.001) with concurrent clinical status.